RxDoctor Payments DataLook up a doctor →

Javier Rojas, MD

Psychiatry · Hickory, NCNPI 1235559667

Payments from drug & device makers

$46,106in general payments, 2019–2025

Across 830 payments — averaging $55.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$24K
  • Idorsia Pharmaceuticals US Inc$8K
  • Johnson & Johnson$2K
  • Bausch Health US, LLC$2K
  • AbbVie$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • plus $8K from 29 others

What the payments were for

  • Speaking & faculty fees$29,54364%
  • Travel & lodging$1,0112%
  • Food & beverage$15,50434%
  • Education$480%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,106 in reported general payments places this provider in the 95th percentile of 1,108 psychiatry providers in North Carolina.

See all psychiatry providers in North Carolina

Medicare billing

Part B allowed, 2024
$49,556
Medicare patients
57
Services billed
526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate18$169,925
VraylarCariprazine Hcl57$97,914
AuvelityDextromethorphan Hbr/Bupropion69$81,100
Invega SustennaPaliperidone Palmitate18$45,381
LybalviOlanzapine/Samidorphan Malate13$23,474
QuviviqDaridorexant Hcl38$18,372
BelsomraSuvorexant36$15,169
Clozapine27$2,791
Trazodone Hcl185$1,462
Quetiapine Fumarate75$1,236
Bupropion XlBupropion Hcl79$1,200
Venlafaxine Hcl ErVenlafaxine Hcl21$1,019
Vilazodone Hcl13$751
Methylphenidate Hcl12$719
Duloxetine Hcl28$701

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$793$169,92518 claims
AbbVieVraylar$1,507$97,91457 claims
Axsome Therapeutics, Inc.Auvelity$521$81,10069 claims
Johnson & JohnsonInvega Sustenna$1,649$45,38118 claims
Alkermes, Inc.Lybalvi$1,192$23,47413 claims
Idorsia Pharmaceuticals US IncQuviviq$7,958$18,37238 claims
MerckBelsomra$19$15,16936 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,108 psychiatry providers in North Carolina.

Other psychiatry in Hickory

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →